These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21079617)

  • 1. No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight.
    Smith DL; Robertson HT; Desmond RA; Nagy TR; Allison DB
    Int J Obes (Lond); 2011 May; 35(5):652-7. PubMed ID: 21079617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
    Wellman PJ; Jones SL; Miller DK
    Pharmacol Biochem Behav; 2003 Apr; 75(1):103-14. PubMed ID: 12759118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
    Thomas GH; Babbs AJ; Chatfield RE; Krülle TM; Widdowson PS; Provost D; McCormack JG
    Obesity (Silver Spring); 2009 Mar; 17(3):467-73. PubMed ID: 19219064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
    Tallett AJ; Blundell JE; Rodgers RJ
    Behav Brain Res; 2009 Mar; 198(2):359-65. PubMed ID: 19061919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does sibutramine work?
    Lean ME
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S8-11. PubMed ID: 11916106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG; Goulder MA;
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of body weight and carcass composition by sibutramine in rats.
    Strack AM; Shu J; Camacho R; Gorski JN; Murphy B; MacIntyre DE; Hickey GJ
    Obes Res; 2002 Mar; 10(3):173-81. PubMed ID: 11886940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locomotor and peripheral effects of sibutramine modulated by 5-HT2 receptors.
    Frassetto SS; Della Santa Rubio A; Lopes JJ; Pereira P; Brum C; Khazzaka M; Vinagre AS
    Can J Physiol Pharmacol; 2006 Dec; 84(12):1239-44. PubMed ID: 17487231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sibutramine--antidepressive agent tested against obesity].
    Rössner S
    Lakartidningen; 2001 Apr; 98(15):1802-3. PubMed ID: 11374008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W; Goa KL
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.
    Grignaschi G; Fanelli E; Scagnol I; Samanin R
    Br J Pharmacol; 1999 Jul; 127(5):1190-4. PubMed ID: 10455265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry.
    Kalia M; O'Callaghan JP; Miller DB; Kramer M
    Brain Res; 2000 Mar; 858(1):92-105. PubMed ID: 10700602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
    Seagle HM; Bessesen DH; Hill JO
    Obes Res; 1998 Mar; 6(2):115-21. PubMed ID: 9545017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locomotion is the major determinant of sibutramine-induced increase in energy expenditure.
    Golozoubova V; Strauss F; Malmlöf K
    Pharmacol Biochem Behav; 2006 Apr; 83(4):517-27. PubMed ID: 16647108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
    Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A
    Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
    Stock MJ
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S25-9. PubMed ID: 9130038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat.
    Jackson HC; Bearham MC; Hutchins LJ; Mazurkiewicz SE; Needham AM; Heal DJ
    Br J Pharmacol; 1997 Aug; 121(8):1613-8. PubMed ID: 9283694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats.
    Rowley HL; Butler SA; Prow MR; Dykes SG; Aspley S; Kilpatrick IC; Heal DJ
    Synapse; 2000 Nov; 38(2):167-76. PubMed ID: 11018791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.